{"entity":{"id":"transthera","kind":"company","name":"TransThera Sciences","aka":[],"tldr":"Chinese biotech running the first phase 3 of a next-generation FGFR inhibitor, tinengotinib, for bile duct cancer that has stopped responding to first-generation FGFR drugs.","summary":"TransThera Sciences, based in Nanjing, is the Chinese biotechnology company running the first phase 3 trial of a next-generation FGFR inhibitor, tinengotinib, for bile duct cancer that has stopped responding to first-generation FGFR drugs. Tinengotinib, also known as TT-00420, is a multi-kinase inhibitor potent against the FGFR2 kinase-domain mutations that drive acquired resistance, and the FIRST-308 phase 3 trial, which compares it with physician's choice chemotherapy in FGFR-altered, FGFR-inhibitor-refractory cholangiocarcinoma, dosed its first US patient in 2025. OnCo links it to biliary tract cancer and to the tinengotinib drug record. Whether a resistance-directed FGFR inhibitor can beat chemotherapy in a population that has already progressed on targeted therapy is the question the trial will answer. Tinengotinib has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.transtherabio.com"}],"tags":[],"related":[],"cancers":["cholangiocarcinoma"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["tinengotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07498478","nct05948475"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Nanjing","country":"CN","companyType":"biotech","website":"https://www.transtherabio.com","investors":[],"funding":[]},"route":"/companies/transthera/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"tinengotinib","kind":"drug","name":"Tinengotinib","route":"/drugs/tinengotinib/"}],"trial":[{"id":"nct07498478","kind":"trial","name":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","route":"/trials/nct07498478/"},{"id":"first-308","kind":"trial","name":"FIRST-308","route":"/trials/first-308/"},{"id":"nct05948475","kind":"trial","name":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","route":"/trials/nct05948475/"}]}}